Tocladesine in Treating Patients With Recurrent or Progressive Metastatic Colorectal Cancer
This trial is active, not recruiting.
|Sponsor||Jonsson Comprehensive Cancer Center|
|Collaborator||National Cancer Institute (NCI)|
|Start date||April 2001|
|Trial identifier||NCT00021268, CDR0000068764, ICN-2000-1, NCI-G01-1979, UCLA-0006008|
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase I trial to study the effectiveness of tocladesine in treating patients who have recurrent or progressive metastatic colorectal cancer.
Male or female participants from 18 years up to 75 years old.
DISEASE CHARACTERISTICS: - Diagnosis of metastatic carcinoma of the colon or rectum - Recurrent or progressive after failing prior fluorouracil and irinotecan chemotherapy, sequentially or in combination, unless unable to tolerate irinotecan - Measurable disease PATIENT CHARACTERISTICS: Age: - 18 to 75 Performance status: - ECOG 0-2 Life expectancy: - Not specified Hematopoietic: - Granulocyte count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 - Hemoglobin at least 10 g/dL Hepatic: - Bilirubin no greater than 1.5 times upper limit of normal (ULN) - AST and ALT no greater than 5 times ULN - PT/aPTT no greater than 1.2 times ULN Renal: - Creatinine no greater than 1.5 mg/dL - Creatinine clearance at least 50 mL/min - No impaired renal function Cardiovascular: - No impaired cardiac function Other: - No active infection - No other malignancy within the past 5 years except basal cell or squamous cell skin cancer - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - See Disease Characteristics - At least 4 weeks since prior chemotherapy Endocrine therapy: - Not specified Radiotherapy: - At least 4 weeks since prior radiotherapy Surgery: - Not specified Other: - No other concurrent anticancer drugs - No concurrent chronic non-steroidal anti-inflammatory agents - No concurrent chronic therapeutic anticoagulation
|Official title||Phase I Study Of Tocladesine In Patients With Colorectal Carcinoma Following Therapy With 5-FU And Irinotecan|
|Description||OBJECTIVES: - Determine the maximum tolerated dose of tocladesine in patients with recurrent or progressive metastatic colorectal cancer. - Determine the qualitative and quantitative toxicity of this drug in these patients. - Assess any therapeutic activity in patients treated with this drug. OUTLINE: This is a dose-escalation, multicenter study. Patients receive tocladesine IV continuously on days 1-5 and 8-12. Treatment repeats every 21 days for up to 10 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of tocladesine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, up to 14 additional patients are treated at this dose level. PROJECTED ACCRUAL: A total of 3-38 patients will be accrued for this study.|
Call for more information